Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 3 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

Rezafungin for candidemia, invasive candidiasis succeeds in phase II trial

16 Oct 2020

The novel echinocandin rezafungin (RZF) appears to be effective against candidemia and invasive candidiasis (IC), with a favourable safety profile, according to the results of the phase II STRIVE trial.

STRIVE randomly assigned 207 adults with systemic signs and mycological confirmation of candidemia and/or IC to one of the following treatment arms: (1) RZF 400 mg once weekly, (2) RZF 400 mg at the first week then 200 mg weekly thereafter (400/200 mg), and (3) caspofungin (CAS) 70 mg as a loading dose followed by 50 mg daily for ≤4 weeks once daily.

Of the patients, 183 had documented Candida infection and were included in the microbiological intent-to-treat population. The species isolated at baseline were mostly Candida albicans (49.7 percent), followed by Candida glabrata (20.2 percent), Candida parapsilosis (15.3 percent), and Candida tropicalis (12.0 percent).

At day 14, overall cure rates were 60.5 percent (46/76) with RZF 400 mg, 76.1 percent (35/46) with RZF 400/200 mg, and 67.2 percent (41/61) with CAS. The respective investigator-assessed clinical cure rates were 69.7 percent (53/76), 80.4 percent (37/46), and 70.5 percent (43/61).

The 30-day all-cause mortality was 15.8 percent with RZF 400 mg, 4.4 percent with RZF 400/200 mg, and 13.1 percent with CAS.

Clearance of infection occurred within 19.5 hours in the combined RZF group and within 22.8 hours in the CAS group.

No concerning safety trends emerged. All-cause mortality through follow-up (days 45–52 for candidemia only or days 52–59 for IC, with or without candidemia) was 15.2 percent (21/138) with RZF and 18.8 percent (13/69) with CAS.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 3 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.